Atezolizumab and bevacizumab as first line therapy in advanced hepatocellular carcinoma: Practical considerations in routine clinical practice

doi:10.4254/wjh.v13.i9.1132

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5597)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-4) series.

Item

Count

PDF

409

WORD

115

HTML

3468

Tables (1-4)

523

Sum=4515

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

481

Download

601

Sum=1082

Sep 27, 2021 (publication date) through Feb 11, 2025

Times Cited of This Article

Times Cited (9)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Hepatol. Sep 27, 2021; 13(9): 1132-1142
Published online Sep 27, 2021. doi: 10.4254/wjh.v13.i9.1132

Table 1 Results of phase Ib GO30140 study

	Arm A	Arm F
	Atezolizumab and bevacizumab combination (n = 104), median follow up 12.4 mo	Atezolizumab and bevacizumab combination (n = 60), median follow up 6.6 mo	Atezolizumab monotherapy (n = 59), median follow up 6.7 mo
ORR, n (%)	37 (36)	12 (20)	10 (17)
CR, n (%)	12 (12)	1 (2)	3 (5)
DCR, n (%)	78 (75)	40 (67)	29 (49)
Median PFS, mo	7.4 (5.6-10.7)	5.6 (3.6-2.4)	3.4 (1.9-5.2)
HR (80%CI)	-	0.55 (0.40-0.74), P value (0.0108)
12 mo PFS (%)	38
12 mo OS (%)	63

ORR: Over all response rates; CR: Complete response; DCR: Disease control rate; PFS: Progression free survival; HR: Hazard ratio; OS: Overall survival.

Citation: Jain A, Chitturi S, Peters G, Yip D. Atezolizumab and bevacizumab as first line therapy in advanced hepatocellular carcinoma: Practical considerations in routine clinical practice. World J Hepatol 2021; 13(9): 1132-1142
URL: https://www.wjgnet.com/1948-5182/full/v13/i9/1132.htm
DOI: https://dx.doi.org/10.4254/wjh.v13.i9.1132